The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cost-effectiveness of three years of adjuvant imatinib in gastrointestinal stromal tumors (GIST).
Myrlene Sanon
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Anju Parthan
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Douglas Taylor
Consultant or Advisory Role - Novartis
Research Funding - Novartis
John Coombs
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Marc Paolantonio
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Medha Sasane
Employment or Leadership Position - Novartis
Stock Ownership - Novartis